iBio, Inc. Form 10-Q Summary
Business Context and Reporting Period
iBio is a biotechnology company commercializing plant-based protein expression technologies, including the iBioLaunch and iBioModulator platforms, and developing selected biopharmaceutical candidates. The filing covers the three months ended September 30, 2014, the first quarter of fiscal 2015. The interim financial statements are unaudited.
Key Financial Metrics
| Metric | Q1 FY2015 | Q1 FY2014 |
|---|---|---|
| Revenue | $819,000 | None |
| Operating loss | $1.416 million | Operating income of $240,000 |
| Net income/(loss) | $(1.410) million | $379,000 |
| Comprehensive income/(loss) | $(1.413) million | $379,000 |
| Basic and diluted EPS | $(0.02) | $0.01 |
| Cash used in operating activities | $570,000 | $911,000 |
Gross margin is not meaningful because the $819,000 of revenue represented technology services performed by Fraunhofer for FioCruz, with an equal amount recorded as research and development expense and no profit recognized on the activity.
- Cash was $3.486 million at September 30, 2014, compared with $3.590 million at June 30, 2014.
- Total assets were $6.657 million and total liabilities were $1.218 million at September 30, 2014.
- Stockholders’ equity was $5.439 million, down from $6.099 million at June 30, 2014.
- The company had no reported debt; current liabilities consisted primarily of accounts payable and accrued expenses.
- Accumulated deficit was $42.612 million.
- Investing activities used $31,000, while financing activities provided $500,000 from an Aspire Capital equity purchase.
Material Changes Versus the Prior Comparable Period
- Revenue increased from zero to $819,000 following an amendment to the FioCruz collaboration and resumption of related services.
- Research and development expense was $1.185 million, compared with a prior-year credit of $489,000. The prior period included a $1.041 million benefit from the Fraunhofer settlement; excluding that item, current-period R&D increased approximately $638,000.
- General and administrative expense increased to $1.050 million from $249,000 as reported. Excluding the prior-year $700,000 settlement-related credit, expense increased approximately $101,000, primarily due to higher intellectual-property legal fees.
- The company moved from net income of $379,000 to a net loss of $1.410 million, largely reflecting the absence of prior-year settlement benefits and higher operating costs.
- Shares issued and outstanding increased to approximately 67.5 million from 65.6 million at June 30, 2014, primarily due to Aspire Capital issuances and the commitment fee.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expects cash on hand and funding available under the Aspire Capital agreement to support activities through September 30, 2015. The filing states that substantial doubt remains regarding the company’s ability to continue as a going concern after available resources are exhausted.
- Aspire Capital committed to purchase up to $10.0 million of common stock over approximately 24 months. During the quarter, it purchased 1,136,354 shares for $500,000 and received 681,818 commitment shares. Subsequent to quarter-end, it purchased 2,858,400 shares for $4.712 million.
- As of November 14, 2014, the company reported selling 3,994,754 shares for $5.2 million under the Aspire agreement, leaving approximately $4.8 million available, subject to market-price and other conditions.
- Subsequent to quarter-end, the company received $824,680 from warrant exercises and issued additional shares through cashless warrant exercises.
- The company remains committed to engage Fraunhofer for at least $3.0 million of work by December 31, 2015. Approximately $1.6 million had been engaged by September 30, leaving about $1.4 million outstanding.
- The company filed litigation against PlantForm alleging interference with contracts and misappropriation of intellectual property. It is seeking equitable relief and damages.
- A putative securities class action was filed against iBio and its chief executive officer. The company had not been served, could not predict the outcome, and could not estimate a potential loss.
- Related-party accounts payable to Novici, in which iBio’s president is a minority stockholder, were approximately $222,000. Related-party R&D expense was also approximately $222,000 for the quarter.
- Key risks include continued operating losses, dependence on equity financing and licensing arrangements, dilution from additional share issuance, intellectual-property disputes, clinical and commercialization uncertainty, and the ability to generate sustainable revenue.
Important Facts for Investors to Verify
- Whether the FioCruz yellow-fever-vaccine collaboration produces recurring revenue or remains a pass-through activity with no margin.
- The timing and terms of remaining Aspire Capital drawdowns, including share dilution and the $0.44 floor-price condition.
- Cash usage and funding availability relative to the company’s stated September 30, 2015 support horizon.
- Progress toward the $3.0 million Fraunhofer work commitment and related cash obligations.
- The status, potential financial exposure, and intellectual-property implications of the PlantForm and securities class-action litigation.
- Development and regulatory progress for the company’s platform technologies and fibrosis-related product candidates.